Icon (NASDAQ:ICLR) updated its FY19 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $6.81-6.95 for the period, compared to the Thomson Reuters consensus estimate of $6.89. The company issued revenue guidance of $2.79-2.83 billion, compared to the consensus revenue estimate of $2.81 billion.Icon also updated its FY 2019
Pre-Market guidance to 6.81-6.95 EPS.
Several brokerages have recently issued reports on ICLR. BidaskClub cut Icon from a buy rating to a hold rating in a research note on Friday, January 10th. Credit Suisse Group reiterated a buy rating and issued a $160.00 price objective on shares of Icon in a research note on Monday, October 28th. Citigroup began coverage on Icon in a research note on Monday, January 6th. They issued a neutral rating and a $185.00 price objective for the company. UBS Group set a $160.00 price objective on Icon and gave the company a hold rating in a research note on Friday, October 25th. Finally, Zacks Investment Research upgraded Icon from a hold rating to a buy rating and set a $191.00 price objective for the company in a research note on Wednesday, December 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $169.56.
Shares of NASDAQ ICLR traded up $2.11 during midday trading on Thursday, hitting $173.71. 4,943 shares of the company’s stock were exchanged, compared to its average volume of 213,955. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.03 and a quick ratio of 2.03. Icon has a twelve month low of $127.58 and a twelve month high of $173.00. The company has a market cap of $9.15 billion, a PE ratio of 27.63, a P/E/G ratio of 2.05 and a beta of 0.70. The firm’s fifty day simple moving average is $166.68 and its 200-day simple moving average is $155.44.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also: Buy Rating
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.